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ABSTRACT Based on our previous mathematical model of the acute myeloblastic
leukemic (AML) state in man, we superimpose a chemotherapeutic drug treatment
regimen. Our calculations suggest that small changes in the protocol can have sig-
nificant effects on the result of treatment. Thus, the optimal period between drug
doses is the S-phase interval of the leukemic cells-about 20h and the greater the
number of doses administered in a given course treatment, the longer the rest interval
should be before the next course is administered. For a patient with a "slow" grow-
ing AML cell population, remission can be achieved with one or two courses of treat-
ment, and further suppression of the leukemic population can be achieved with con-
tinued courses of treatment. However, for patients with a "fast" growing AML cell
population, a similar aggressive treatment regimen succeeds in achieving remission
status only at the cost of very great toxic effects on the normal neutrophil population
and its precursors.
INTRODUCTION
The knowledge that some chemotherapeutic agents such as arabinosyl cytosine (ara-C)
are cell-cycle specific has provided a rational basis for drug-treatment protocols that
depend on the kinetic properties of the cell population to be eliminated. In the
hands of Skipper and his collaborators (1), such consideration has produced protocols
that have succeeded in curing mice of L-1210 leukemia. A parallel development in the
treatment of human leukemia has been the introduction of the L-2 protocol in the
treatment of acute lymphoblastic leukemia (ALL) by investigators at the Memorial
Sloan-Kettering Cancer Center (2-4). In addition, the L-6 protocol has been intro-
duced for the treatment of acute myeloblastic leukemia (AML) and of related myeloid
forms of this disease (5). These protocols have significantly extended both the inci-
dence of remission and the mean survival time of all patients. Thus (6), the incidence
of remission of 56% in previously untreated patients was achieved, with a median
duration of remission of 10 mo. The median survival time of responders was 2 yr,
whereas prior to 1966, the median survival time of adults with AML, was about 4 mo.
The essential rationale of the L-6 protocol has been previously reported (7, 8):
Drug doses of the cycle-specific drug ara-C in combination with 6-thioguanine (TG)
are administered sufficiently close together in time so that leukemic cells are prevented
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from completing S-phase without being exposed to a lethal drug concentration. The
duration of S-phase of leukemic cells is about 20 h (9). Treatments are continued
until marrow depression or other toxic effects become too great, and a rest period is
instituted, usually of 3 wk duration, to permit recovery of the normal marrow cells.
The entire course of treatment is then repeated, if necessary, to a remission stage.
Aside from the significant achievement of extending the life of the patients involved,
the important theoretical accomplishment of the introduction of these protocols is the
principle that the protocol, which is to say the temporal course of administration of
the chemotherapeutic agent, and not just the drug itself, is vital for the success of
chemotherapy. The empirical nature of this accomplishment, achieved after many
years of trial and error, leads very naturally to the suggestion that a mathematical
model of the cell proliferation and treatment process could perhaps provide a com-
pletely deductive basis for success (or failure) of a chemotherapeutic drug regimen in
the treatment of cancer. This conception has in fact appealed to a number of mathe-
matically minded investigators of the cancer problem (10-14). The significance of
mathematical modeling in understanding the kinetics of leukocyte proliferation and of
the acute leukemic state has by now been generally recognized (15-18).
Here we shall describe our own efforts to model the essential kinetic features of the
L-6 protocol. Our goal is to aid therapy and the medical chemotherapist, who is im-
pelled to treat his leukemic patient in the best way he knows how, in the face of the
many uncertainties about the nature of the disease state AML. Because of these uncer-
tainties, we must make many presumptions and assumptions about the nature of the
disease, as well as normal granulopoiesis. However, it is important to recognize that
whether one detail of the model is correct or not is not so important as the general
scheme: at the present time we are interested in suggesting improved strategies in
chemotherapy, rather than the matching of a particular treatment regimen to a given
patient.
Our model is purely a kinetic one that concerns itself with growth, birth, and death
processes of cell populations, and associated homeostatic mechanisms. To represent
the latter, only the existence of such control mechanisms is assumed, rather than the
biological or biochemical means by which it is achieved. The search for such mecha-
nisms, by a granulopoietic chalone (19), or by colony-stimulating factors (CSF)
(20, 21) and CSF inhibitors (22), is of course being actively pursued in its own right. In
previous work we have suggested a model of the neutrophil production system in
normal man (23), as well as a model of the acute myeloblastic leukemic state (24).
The basic features of our model can be described succinctly as follows. In the marrow
of normal man there is a proliferative state and a nonproliferative state (see Fig. 1).
The proliferative state consists of two compartments, an active or cycling compart-
ment A and a resting compartment Go. In Go, the decision is made as to whether a
precursor cell goes back to the active state and proliferates, or travels to the nonpro-
liferative state, in which it matures, and is expelled to the blood as a young neutrophil.
In the steady state, half of the cells leaving Go go to A and divide, while half go on to
mature. If the population wishes to expand (contract), a greater (lesser) fraction of the
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THE NORMAL STATE
FIGURE I Schematic model of the normal neutrophil production system. The control functions
a, f,, and y represent the fractional rate of release of cells along the indicated pathways,
and depend on the total number of cells in the system (in the case of a and f,), or in the
blood (in the case of y). A is the time rate of cell disappearance from the blood compartment.
Go cells are sent to A than to the maturation compartment M. The decision as to
which evantuality occurs depends homeostatically on whether the total population of
neutrophils and precursors is greater or smaller than the prescribed total steady-state
population number N, where N - 1012 cells. There is also a mechanism in the nonpro-
liferative state by means of which young neutrophils may be expelled to the blood, in
response to need from the blood.
In the acute myeloblastic leukemic state, we adopt the point of view of Clarkson (7)
that side by side with the normal neutrophil production system, there exists a distinct
leukemic cell population. By and large it is a nonmaturing cell population, but it is
controlled homeostatically in a manner similar to the normal population (see Fig. 2).
However, the homeostatic level N' of the leukemic population is greater than the cor-
responding level of the normal cells, say N' - 3 x 1012. Furthermore, the homeo-
static control mechanism for the normal cells fails to recognize the leukemic cells as
different from normal cells. Consequently, as the leukemic cells increase in their desire
to reach their homeostatic level N', the normal cell production system is progressively
curtailed as the leukemic cells approach and surpass the normal homeostatic level N.
Thus, the principal consequence of the exposure of the normal neutrophil population
to the leukemic population is to destabilize the normal homeostatic control of the
nonleukemic cell population. The combined system possesses a new stable state to
which the population is (unfortunately) driven, in which all cells are leukemic, while
normal neutrophils and their precursors disappear. Hence, we do not view the ques-
tion as to whether leukemia is a neoplasm or a disorder of hemopoietic regulation as an
G
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FIGURE 2 Schematic model of the leukemic cell population in the acute myeloblastic state.
Primed compartments and control functions are counterparts of the normal neutrophil system.
Leukemia marrow myeloblasts not actively proliferating are assumed to be in the resting state
G,.
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TABLE I
STEADY-STATE PARAMETERS OF THE NEUTROPHIL
PRODUCTION SYSTEM IN A NORMAL 70 kg MAN*
Compartment Mean transit time Population no.
h
GI 12 6.0 x 1010
S 15 7.5 x 1010
G2 + m 3 1.5 x 10'0
A 30 1.51 x 101
Go 20 1.01 x1011
M 96 4.85x10"
R 90 4.54 x 10"
B 9.7 0.49 x 1011
Sum 246 1.24 X1012
*Taken from ref. 23.
either/or proposition (25). Rather, in our model, the existence of the. neoplasm or
leukemic cell population leads to destabilization of the normal regulated state.
The mathematical formulation and other details of the complete model can be found
elsewhere (23, 24). The parameters that characterize the normal steady-state behavior
of the neutrophil production system are summarized in Table I. The control func-
tions a and f, which determine the fractional rates of cells leaving Go to enter either
the compartments A or M, respectively, were represented either by a power law (23),
or by a logarithmic law (24) with parameter values as shown in Table II. Previous
experience with representing perturbations of the normal neutrophil system such as
leukophoresis experiments, suggest that the power law, which has a more rapid rate of
response than the logarithmic law, is more successful than the logarithmic law in
doing so.
The principal effect of varying the parameters entering into either of these functions
is to alter the fractional rate of exponential growth of the normal population, or re-
covery rate, in response to depletion as by chemotherapeutic insult. It can be shown
(24) that this fractional growth rate is proportional to the difference a, - ,,, where
a, and #I are the dynamical parameters entering into the functions a and 6. Thus,
TABLE II
PARAMETERS OF THE CONTROL FUNCTIONS* a AND ,B
Control
function aO a I
h-1 h-1 h-1
Logarithmic 0.05 0.0375 0.00417 - 1.24 x 1012
Power 0.05 0.05 0.00417 3 1.24 x 1012
* From refs. 23 and 24.
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TABLE III
STEADY-STATE PARAMETERS OF THE LEUKEMIC
CELL POPULATION IN AML*
Compartment Mean transit time Population no.
h
G;, 0 0
St 20 2.08 x 1011
G' + mr 5 0.52 x 101l
A' 25 2.60x 10"
G0 227 2.36 x 1012
B' 36 3.75 x l0"
Sum 288 3 x 1012
*Taken from ref. 24.
the greater the excess of ai with respect to f, the greater is the recovery rate. The
control functions a' and d' were represented by a logarithmic law.
The parameters determining the quasi-steady-state behavior of the leukemic cell
population, characterizing the very late stages of AML, are given in Table III. By
varying a' and fS, models of leukemic cell populations with differing dynamical
characteristics, that is to say natural growth rates and natural lifetimes, can be repre-
sented. Essentially two different models were investigated, a fast growing cell popula-
tion and a slow growing cell population. The parameters a' and , for these cases,
together with the doubling time (in the presence of a normal neutrophil population)
and mean lifetime (defined as the time needed for the population number to reach 1012,
starting from one cell), are given in Table IV.
The behavior of the leukemic blood cell population as a function of time is displayed
in Figs. 3 and 4 for the two cases. This behavior is very similar to that of the total
population. The normal blood cells maintain their normal level during the silent and
unobserved period of exponential growth of the leukemic population, and then pre-
cipitously disappear when the leukemic population attains a detectable level of about
10" cells.
In modeling a drug-treatment regimen, we superimpose a killing schedule on the
natural history of the disease. Thus, we assume that the effect of administration of a
TABLE IV
PARAMETERS OF THE CONTROL FUNCTIONS OF TWO LEUKEMIC POPULATIONS
Model aaj W Doubling* Mean* VModel ct0 cYl ; time lifetime
h-I h-1 h-1 d d
Fast 0.0044 0.0044 0.00044 12 470 3 x 1012
Slow 0.0044 0.0022 0.0011 56 1560 3 x 101
*Calculated from Equations 11 and 12 in ref. 24.
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FIGURE 3 The ordinate represents, on a loglo scale, the number of normal neutrophils in the
blood NB, the number of leukemic myeloblasts NB,S and the sum NB + NB,. as a function of time
T in days, assuming 10 leukemic myeloblasts and introduced into the marrow at time zero. Pa-
rameters of the control functions a' and ,B', which determine the growth rate of this "fast" leu-
kemic population, are given in Table IV.
dose of a drug or drug combination such as ara-C plus TG is to kill a fixed fraction f
of all cells in S-phase, whether normal or leukemic. For purposes of calculation, the
compartments A and A' are each subdivided into three compartments, namely, GI, S,
and G2 + m. In all our calculations, it was assumed that f = 0.9 so that 900% of all
cells in S were killed at the time of the drug administration. We considered the effect
of treatment on both the fast and slow leukemic cell models. In simulating the L-6
protocol, we assumed that the drug combination was administered with a periodicity
P for n times. Following this, a rest period of duration rR was imposed. We shall
refer to the administration of a chemotherapeutic agent n times with periodicity P fol-
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FIGURE 4 The same quantities as shown in Fig. 3 are here represented for the "slow" leukemic
population of Table IV.
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lowed by a rest period rR as a course of treatment. The regimen consisted of the course
of treatment repeated six times. This corresponds to the most intensive treatment
regimen attempted with the L-6 protocol. It is to be noted that the regimen contains
two periodicities: a minor period equal to P, and a major period represented by the
time interval between two successive rest periods. This major period equals TR + n P.
In the clinic, the success of chemotherapy is measured firstly by the attainment of a
remission status, which means the apparent elimination of leukemic myeloblasts from
the blood and the reduction of myeloblasts in the marrow to normal levels. Such an
apparent disappearance is attained if there is an approximately 100-fold decrease in
the leukemic cell number. A precise clinical definition, which depends on the hemo-
poietic status of other cells, can be found elsewhere (5). For our purposes we shall
conveniently define a state of remission as the reduction of the leukemic cell population
to 1010 or less. We know from clinical experience that actual remissions can last for
many months, and sometimes for years. Presumably, immunological or other factors
are coming into play, not represented in our model, which make this possible. Hence,
"Asuccess" in our model should be interpreted as the absolute reduction in the number
of leukemic cells at a given time, while the toxic effect of chemotherapy is not too
large: the normal population is at an acceptable level of depletion.
RESULTS OF CALCULATIONS
In attempting to assess the effects of the VAMP and BIKE chemotherapeutic
protocols on patients with ALL, Freireich et al. (26) interpreted variability in ob-
served remission time as a consequence of the variability in the number of cells killed
in therapy. Such a view leaves unanswered the question as to why the same protocol
applied to two different patients can differ by many orders of magnitude in the number
of neoplastic cells killed. It would seem that an equally plausible interpretation is the
one we have implicitly adopted herein: for a given protocol, variability in remission
time is essentially a consequence of variability in doubling time.
There were several important effects that we attempted to investigate. First, we tried
to examine the effect of variation of the periodicity P. Second, we varied the number
of times n that the drug was administered. Third, we varied the time interval of rest
period TR. Fig. 5 displays the temporal effect on the total populations of both the nor-
mal and leukemic cells of setting P = 15, 18, 20, or 24 (in units of hours). We had
anticipated on naive grounds that the optimal periodicity for killing the leukemic pop-
ulation was P = 20, because the S-phase interval for the leukemic cells was 20 h, and
hence such a schedule would kill leukemic cells at maximal efficiency. Of course, a
periodicity of less than 20 h would also kill as many leukemic cells during a course of
treatment, although the 20 h schedule extends over a longer period for a given number
of drug administrations. However, the P = 15 schedule was expected to be most toxic
for the normal cells, by the same argument, because the S-phase period of the normal
cells was 15 h. It can be seen from Fig. 5 that these expectations were borne out by the
calculations. The most severe depletion of the leukemic cells occurred for P = 20 hr.
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FIGURE 5 The ordinate represents, on a log10 scale, the total number of normal neutrophils
and their precursors (labeled N) and the total number of leukemic myeloblasts (labeled L),
as a function of time T during a drug regimen consisting of six courses of treatment. The treat-
ment commences on day zero when the fraction of marrow leukemic myeloblasts (ratio of cells
in A ' + G6 to cells in A + G0 + M + R) equals 0.25. The normal population is represented by
the parameters of Table I and a logarithmic control function (see Table 11), while the leukemic
population is represented by the parameters of Table III and the "slow" model of Table IV.
The treatment regimen parameters were as follows: Fraction of all cells f in S killed by a
drug dose = 0.9; number of drug doses in each course of treatment was n = 10; rest period be-
tween successive courses of treatment was TR = 3 wk; number of courses of treatment was six.
(a) Periodicity between drug doses wasP = 15 h; (b) P = 18; (c) P = 20; (d) P = 24.
In these calculations, the rest period TR was assumed to equal three wk, as in the actual
L-6 protocol. The number of drug administrations in each major period was taken to
be n = 10. The normal control functions were assumed to obey the logarithmic law.
The leukemic population was represented by the slow model of Table II. It can be
noted in the figures that the normal population always recovers much more rapidly
than the leukemic population during the rest phases of the treatment. Perhaps slightly
surprising is the comparison of Figs. 5b and 5d, which shows that the schedule with
P = 24 appears to do as well as the schedule with P = 18. In fact, the former has a less
toxic effect than the latter, as can be seen by comparing the minima in the normal pop-
ulation in the two cases.
The same schedule as above with P = 20 can not successfully deplete the fast
growing leukemic population represented by the fast model, as shown in Fig. 6. Fur-
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FIGURE 6 Same as Fig. 5 except that the normal population was represented by the power control
function of Table IV, the leukemic population was represented by the "fast" model of Table IV,
and P = 20.
thermore, the treatment has the additional undesirable quality of rapidly eliminating
the normal population. The latter was modeled by a power law, with the same dy-
namical parameter values utilized in ref. 23 (a0 = 0.05/h, a, = 0.05 h, #8 = 0.025 h).
Thus, the relative rapidity with which normal cells are sent into active phase in this
model makes them more susceptible to the toxic effect of treatment. Also inimical
to the recovery of the normal cell population during the rest periods is the presence of
the relatively large leukemic cell population. Because normal cells identify leukemic
cells as normal, the normal cell depletion does not appear as large to the control func-
tions as it actually is.
In a further set of calculations, illustrated in Fig. 7, we retained the power law but
increased the growth rate of the underpopulated normal cells by reducing the value of
Al to 0.00417/h, and thus increasing the difference a, - #,. In addition, we extended
the sequence of drug administrations to 20 in each of the major periods. For Fig. 7a,
the recovery interval was assumed to be 3 wk. Although the normal population is here
being eliminated, the effect of increasing n to 20 also leads to the elimination of the
leukemic population. For Fig. 7b, the rest period was increased to 4 wk, with a con-
comitant dramatic improvement in the recovery behavior of the normal population,
although the leukemic population is still being eliminated by this extremely intensive
course of treatment. For Fig. 7c, the rest period was increased to 5 wk, and the re-
sults show that this period is too long. The leukemic cells are able to recover, and they
are not reduced in number relative to the normal cells.
In the next set of calculations, illustrated in Fig. 8, the modeling of the normal
population by a power law was retained, but the leukemic population was assumed to
be the slow model. The treatment regimen is the same in this case as for that shown in
Fig. 5c, so that the behavior of the leukemic population is predicatbly the same. How-
ever, it can be seen from a comparison of the behavior of the normal populations in
RUBINOW AND LEBOWITZ Mathematical Model of Chemotherapyfor AML 1265
t N.
2.0
CL
-2 0 20 40 60 60 100 120 140 160 180 200 220 2 40260
T DAYS
FIGURE 7 Sameas for Fig. 6 except that ,8 = 0.00417/h, and the number of drug doses per
treatment course n = 20. (a) The rest period was TR = 3 wk; (b) TR = 4 wk; (c) TR = 5 wk.
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FIGURE 8 Same as for Fig. 5 c except that the normal population is represented by the power
law of Table II. (a)n = 10; (b)n = 20.
Figs. 5c and 8a that the rate of recovery of the normal population following depletion
from a course of treatment is more rapid for the power function. In both cases, it is
seen that the total leukemic population is reduced to about 1010 cells after only one or
two courses of treatment, in other words, a remission status is attained.
In Fig. 8b is shown the effect of the more aggressive treatment of the same popula-
tion with n increased to 20. Here it is seen that the leukemic population is theoretically
eliminated during the fifth course of treatment, although the toxic effect on the normal
population is very great, and must be considered as unacceptable. (Perhaps the use of
leukocyte transfusions or other support mechanisms could make such a course of treat-
ment feasible.) We infer that the introduction of a 4 wk rest period in conjunction with
n = 20 would benefit the normal population to a much greater extent than it would the
leukemic population.
DISCUSSION AND COMPARISON WITH CLINICAL RESULTS
We are well aware of the many inadequacies of our model. Disease states such as
smoldering leukemia may not be adequately represented by any set of parameter
values. The toxic effect of chemotherapy on other cells in the body such as the epi-
thelial cells in the gut is disregarded. The behavior of the leukemic population follow-
ing the attainment of a state of remission is not correct, as we have indicated above.
Variability of the S-phase is neglected. The possibility that a dose of ara-C inhibits
cells from passing the G, - S boundary (progression delay), as suggested by simula-
tion studies of the effects of ara-C on L- 1210 leukemia,' is not accounted for, although
the model could be easily adapted to do so.
Nevertheless, as regards the kinetic characteristics of the normal neutrophil produc-
tion system and of leukemic cells in AML, we believe our model does represent some
present day experience in a reasonably semi-quantitative and realistic manner. There-
fore, it seems fair to pose the following questions to it. What are the kinetic implica-
ILincoln, T. Talk presented at Conference on Cell Kinetics and Cancer Chemotherapy, Annapolis, Md.,
Nov. 4-6, 1975.
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tions of this knowledge in regard to chemotherapeutic regimens in the treatment of
AML, and how can this knowledge be used to advantage? Can the L-6 protocol be im-
proved merely by varying the temporal sequence of events, such as the major and
minor periodicities, the duration of the rest period, the number of courses of treatment,
and so forth? The analyses of our model of the L-6 protocol suggest that the answer
to this last question is yes.
Our calculations show that significant changes occur with seemingly small altera-
tions in scheduling parameters. For example, the theoretical results shown in Figs.
5-8 suggest that the optimum periodicity of drug doses is equal to that of the S-phase
interval of leukemic cells, or 20 h. It is of interest to compare the latter conclu-
sion with the actual practice of the L-6 regimen, which called for a periodicity of 12 h.
Such a periodicity is roughly analogous to our calculations using a 15 h periodicity,
which we found to be most unfavorable, because the toxic effect is severest. The remis-
sion rate achieved among 88 evaluable patients treated with the L-6 protocol was
56% (6). On the other hand, prior to the introduction of the L-6 protocol in 1970,
of 36 evaluable patients treated with daily doses of ara-C plus TG, but without rest
periods, 53% had complete or partial remissions. Hence, the use of a shorter period
did not significantly increase the incidence of remission. In fact, the presumed ad-
vantage of the introduction of a rest period during treatment courses may have been
counterbalanced by a disadvantage of utilizing a shorter period.
Our calculations also suggest that the more intensive a course of treatment is,
the longer the rest period following it should be. We assumed, as in the actual L-6
protocol, that a course of 10 doses is followed by a rest interval of 3 wk duration.
However, when 20 doses per course was utilized, then a longer rest period of about
4 wk duration is better than either 3 or 5 wk duration. In clinical practice the rest
period apparently was variable (6), and depended on the clinical assessment of how
well a patient had recuperated from the toxic effects of the previous dosage course. In
this connection it should be noted that all our calculations were based on the initiation
of therapy at a time when the marrow leukemic fraction equaled 0.25. In clinical
practice, it can be presumed that the initiation of treatment could and often did occur
at a later stage of the disease, when prognosis of therapeutic outcome is less favor-
able, from both a theoretical and empirical viewpoint, because the ability of the nor-
mal marrow to recover from the effects of treatment is considerably reduced.
It was very gratifying that two theoretical outcomes of our calculations were also
observed in clinical practice. One was that in a case of favorable treatment, a remis-
sion is obtained after only one or two courses of treatment. In 20 out of the 49 ob-
served remissions, 20 required exactly two courses of treatment. In all our calculations,
the treatment was continued for six courses of treatment. In those cases where treat-
ment was unfavorable after one or two courses because either the toxic effects were too
great, or remission was not achieved, then continuing the treatment for six courses
was usually even more detrimental to the normal population as compared with the
leukemic population (see Figs. 6-7).
The L-6 protocol was actually carried out in several variations. In one of these,
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regimen II, three additional courses of treatment were administered following the
attainment of an M- 1 marrow, and in nonresponders treatment was continued in an
effort to achieve a remission status. This regimen was the least successful variation
in achieving remission: the success rate was 18 out of 47 patients, or a 41% success
rate. Furthermore, the median survival time of nonresponders was less than 2 mo. As
suggested by Clarkson et al. (6), the more intensive treatment may have actually
shortened survival time in these latter cases. A possible explanation, which is con-
sistent with the results shown in Fig. 6, for example, is that in these cases the leukemic
cell population is growing too rapidly and the toxicity effect is too large for the net
effect of treatment to be beneficial.
However, the results shown in Figs. 5b-d and 8a suggest that, for a patient who
does achieve a remission status, aggressive continuation of the chemotherapy with ad-
ditional courses of treatment is advantageous, and in principle at least, as shown in
Fig. 8b, could succeed in completely eliminating the neoplasm. Experience suggests
that the better the remission status, the longer is the survival time. Hence, we con-
clude that the concept of aggressive continuation of chemotherapy should not be
abandoned, but only for good responders, that is, individuals who do achieve remis-
sion status after two courses of treatment.
We found that for the fast growing leukemia, which had a natural lifetime of about
2 yr or so, treatment could be successful if very large toxic effects were acceptable. In
contrast, treatment could be successful against the slow growing leukemia without
such large toxic effects. This conclusion perhaps receives some clinical support from
two recent studies of the correlations between kinetic parameters observed before the
onset of treatment and the response to chemotherapy.2 These investigators found that
among those who achieved remission, an initial high labeling index (interpreted as a
fast growing leukemia) was an unfavorable prognostic sign with regard to length of
remission.
Our considerations emphasize once again our lack of knowledge of the dynamical
behavior of the perturbed normal neutrophil population and of the AML cell popula-
tion. The acquisition of such knowledge could be very beneficial in enhancing our
understanding of the neutrophil system and in improving the strategy of treatment of
AML by chemotherapy.
SUMMARY
We find that there are two important differences between the kinetic behavior of nor-
mal and leukemic cell populations that appear to be exploitable by means of regulation
of chemotherapeutic protocols. One difference is that the normal population possesses
a faster recovery rate from the cytocidal action of a course of treatment, than does the
2Vogler, W. R., W. B. Kremer, W. H. Knospe, G. A. Omura, and K. Tornyos. 1976. Synchronization with
phase specific agents in leukemia and correlation with clinical response to chemotherapy. Submitted for
publication; Hart, J. S., S. L. George, E. J. Freireich, G. P. Bodey, R. C. Nickerson, and E. Frei, 111. 1976.
Prognostic significance of pretreatment proliferative activity in adult acute leukemia. Submitted for pub-
lication.
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leukemic population. However, in taking advantage of this difference, the length of
the recovery period between two successive courses of treatment is a significant
parameter that needs to be carefully adjusted. The second difference, which clinical
investigators do not appear to have tried to take advantage of, is in the duration of
S-phase in the two populations.
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